Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:4.1.1.17 (ornithine decarboxylase)
 6,351 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Acute mitochondrial insult has been suggested as a primary reason for the clinical, histopathological and biochemical abnormalities seen in Reye's syndrome. However, the etiology of mitochondrial dysfunction has not been identified. Polyamines have been known to alter the mitochondrial structure and function. Influenza infection may cause an increase in ornithine decarboxylase activity and thereby channel ornithine for polyamine biosynthesis, leading to mitochondrial dysfunction in Reye's syndrome. To test this hypothesis, the hepatic concentrations of polyamines, polyamine-metabolizing enzymes and urea cycle enzyme activities in Reye's syndrome patients were determined and compared with patients who died from illnesses other than Reye's syndrome. The hepatic concentration of putrescine, spermidine and spermine were increased in Reye's syndrome patients. The activity of ornithine decarboxylase was elevated but, due to the small number of samples, these values did not reach statistical significance. Ornithine carbamoyltransferase activity was decreased in the liver of Reye's syndrome patients. Our results suggest that increased synthesis of polyamines from ornithine may initiate mitochondrial injury in Reye's syndrome.
 ...
PMID:Hepatic polyamine metabolism in children with Reye's syndrome. 182 65

In the initial stages of Reye's Syndrome, following an influenza infection, the viral RNA polymerase activates liver host cell ornithine decarboxylase by combining with this enzyme. Once the reaction has occurred, ornithine decarboxylase is no longer available to combine with and to activate host cell RNA polymerase. The virally activated ornithine decarboxylase removes ornithine from participation in the urea cycle by metabolizing ornithine to putrescine which, in turn, is metabolized to spermidine. Once ornithine has been removed from participation in the urea cycle, mitochondrial carbamoyl phosphate levels increase until the carbamoyl phosphate passes from the mitochondria into the cytosol where it is metabolized by the de novo pyrimidine synthesis pathway. Through the implementation of this process, the virus has insured that: host cell RNA polymerase in liver cells is inactivated, viral RNA polymerase has complete access to newly synthesized pyrimidines, production of pyrimidines for the synthesis of viral messenger RNA is initiated, spermidine, a mRNA stabilizer is produced, many of the components necessary for viral mRNA synthesis are provided by the host cell's RNA synthesizing mechanism.
 ...
PMID:The viral mechanism of Reye's syndrome. 637 95

Two-fold immunization of Balb/c mice with a vaccinia virus recombinant expressing the NP protein of influenza A/PR8/34 (H1N1) virus under the control of a strong synthetic promoter induced specific antibodies and protected animals against low-dose challenge by mouse-adapted heterosubtypic variants of human A/Aichi2/68 (H3N2) and avian A/Mallard/Pennsylvania/10218/84 (H5N2) influenza virus strains. The surviving immunized animals had lower anti-hemagglutinin antibody titers compared to non-immunized mice. There was no difference in viral titers in lungs of immunized and non-immunized animals that succumbed to the infection. In order to try to increase immune system presentation of NP-protein-derived peptides, and thereby increase their immunogenicity, we constructed another vaccinia-based NP-expressing recombinant containing a rapid proteolysis signal covalently bound to the NP protein. This sequence, derived from the mouse ornithine decarboxylase gene has been shown to increase degradation of various proteins. However, we found that when used as part of a recombinant NP, this signal neither increased its proteolytic degradation, nor was it more efficient in the induction of a protective response against influenza infection.
 ...
PMID:Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. 1629 96